Skip to main content
Grant Details

Grant Number: 1UM1CA233033-01 Interpret this number
Primary Investigator: Cheville, Andrea
Organization: Mayo Clinic Rochester
Project Title: Enhanced, Ehr-Facilitated Cancer Symptom Control (E2C2) Pragmatic Clinical Trial
Fiscal Year: 2018


Cancer and its treatment engender disabling symptoms that are frequently undertreated, and associated with needlessly increased healthcare utilization, non-adherence to oncologic treatments, and reduced survival. The key to addressing this damaging situation lies in reliably detecting symptoms and providing evidence-based care. Of note, the National Academy of Medicine has identified systematic screening with patient reported outcomes (PROs) as critical, not only to symptom control, but also to enhancing the patient centricity and effectiveness of cancer care in general. Unfortunately, experience has shown that simply presenting PRO data to over-loaded, treatment-focused clinicians has minimal or no impact on the outcomes of patients with many diseases, including cancer. On the other hand, providing these data to mid-level providers and entrusting them to initiate, monitor and adapt individually tailored symptom management plans has proven robustly effective in the control of cancer-related and other symptoms. However, the high resource requirements of this approach have heretofore limited its dissemination and scalability. Encouragingly, such resource intense care is not always required for meaningfully benefit, as attested by the effectiveness of interventions that provide patients experiencing mild or moderate with self-management education. This application recognizes the need for both low- and high-touch approaches to cancer symptom control and proposes the Enhanced, EHR-facilitated Cancer Symptom Control (E2C2) pragmatic clinical trial to test a bundled intervention that leverages EHR interface and clinical decision support functionalities to operationalize the population-level implementation of an approach that automatically triages symptomatic patients to low-touch automated self-management (Level 1), or high-touch nurse care management (Level 2), both validated, depending on PRO scores, as well as patient and clinical factors. The E2C2 intervention will target Sleep disturbance, Pain, Anxiety, Depression, and Energy deficit/fatigue, the SPADE pentad which represents the most prevalent and potentially treatable group of overlapping cancer symptoms. To rigorously assess the effectiveness of discrete E2C2 intervention components, we will initially test a Stage 1 Symptom Control Bundle for 12 months, after which we will add a Stage 2 Implementation Bundle. The trial's stepped wedge design will randomize the order of E2C2 implementation among 21 clusters. Clusters will be defined at the level of the cancer care team, and will be randomized to one of five different tranches to receive the intervention at staggered 6 month intervals. Outcomes will include SPADE symptom scores (primary), physical function, social participation, quality of life, distress, healthcare utilization, adherence to cancer treatment, and vital status which will be collected for 9-12 months during each trial phase; pre-E2C2, Stage 1 and Stage 2. A multi-stakeholder, mixed methods approach will be used to comprehensively assess the impact of the Stage 2 Implementation Bundle, as well as both Stages' impact on rurally-based and elderly patients, groups prone to disparities in symptom control.


Receptivity to a Nurse-Led Symptom Management Intervention Among Highly Symptomatic Patients With Cancer.
Authors: Wintheiser G.A. , Ruddy K.J. , Herrin J. , Rahman P.A. , Pachman D.R. , Leppin A.L. , Rutten L.J.F. , Lee M.K. , Griffin J.M. , Tofthagen C. , et al. .
Source: Journal of the National Cancer Institute, 2022-03-08; 114(3), p. 458-466.
PMID: 34508602
Related Citations

Pragmatic cluster randomized trial to evaluate effectiveness and implementation of enhanced EHR-facilitated cancer symptom control (E2C2).
Authors: Finney Rutten L.J. , Ruddy K.J. , Chlan L.L. , Griffin J.M. , Herrin J. , Leppin A.L. , Pachman D.R. , Ridgeway J.L. , Rahman P.A. , Storlie C.B. , et al. .
Source: Trials, 2020-06-05; 21(1), p. 480.
EPub date: 2020-06-05.
PMID: 32503661
Related Citations

Back to Top